Clinical Trials Logo

Clinical Trial Summary

The novel oral anticoagulants such as rivaroxaban, apixaban and dabigatran, specifically target either thrombin or factor Xa/IIa. These new agents are included as an option for prevention of thromboembolic disease or recurrent stroke in patients with non-valvular atrial fibrillation in guidelines.

Although the benefits and risks of anticoagulation and antiplatelet therapy have been fully assessed, and reasonable anticoagulation and antiplatelet therapies have been formulated, the therapeutic effect still largely depends on the quality control during the treatment. Many patients discontinue anticoagulant therapy after discharge or after a period of treatment, and the risk of thrombosis increases. Because non-vitamin K antagonist oral anticoagulants (NOACs) does not need routine monitoring, patients tend to ignore the regular medication, thus affecting drug compliance. Because of the short half-life of NOACs, if patients do not take it regularly, not only can not achieve the effectiveness of anticoagulation, but also reduce the safety of medication. More and more researchers have realized that medication adherence plays a key role in medical management. In order to improve the efficacy and safety of NOACs and the compliance of patients with NOACs, the guidelines emphasize that supplementary measures can be taken, such as pharmacists participating in the network pharmacy database, attaching importance to the medication education of patients and their families, formulating a strict follow-up plan and professional outpatient follow-up.


Clinical Trial Description

Patients with new oral anticoagulants will be included in the study. After the signing of the informed consent, blood samples were collected to detect the anti Xa factor activity after taking the drugs. Meanwhile, the medication compliance of the patients during the treatment was also collected.

Dedicated tests based on anti-Xa activity for rivaroxaban and apixaban and anti-IIa activity for dabigatran concentration was conducted. Blood samples are divided into peak concentration and valley concentration. Peak concentration (Cmax) refers to the highest serum concentration after administration for at least one week in the study. Valley concentration (Cmin), the lowest concentration during administration, is usually obtained from the lowest concentration between the initial time of administration and the next time the drug is administered at a steady state (continuous medication for more than 1 weeks.).

A compliance questionnaire was conducted to collect the compliance of the drug during treatment. The Morisky, Green, and Levine Adherence Scale (MGLS) was used to evaluate the medication adherence of non-vitamin K antagonist oral anticoagulants (NOACs) patients.

Based on the results of data analysis, the correlation between anti Xa/IIa activity test results and medication compliance was analyzed, making the anti Xa/IIa activity concentration a simple measure to predict the compliance of patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03666962
Study type Observational
Source Peking University First Hospital
Contact Qian Xiang, Ph.D
Phone +86 010 66110802
Email xiangqz@126.com
Status Recruiting
Phase
Start date September 1, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Terminated NCT02128841 - Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. Phase 2
Recruiting NCT03670446 - Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants:A Study on Behavioral Patterns N/A
Recruiting NCT04796714 - AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE Phase 4
Completed NCT01033279 - Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy N/A
Completed NCT00287313 - Daily Vitamin K in Patients on Warfarin With Unstable INRs N/A
Completed NCT00222638 - Influenza Vaccination and Oral Anticoagulant Therapy Phase 4
Active, not recruiting NCT06203795 - Dialysis Performance of the FX CorAL Membrane N/A
Completed NCT03864900 - Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence N/A
Active, not recruiting NCT06401863 - Shared Decision for Drug Interactions in Oral Anticoagulation N/A
Not yet recruiting NCT04977076 - Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention N/A
Recruiting NCT04861103 - Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH) Phase 4
Completed NCT01653405 - Improving Anticoagulation Control in VISN 1 N/A
Not yet recruiting NCT05820854 - Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
Completed NCT04681482 - Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
Not yet recruiting NCT06137794 - Application of "I-Anticoagulation"in Patients With Atrial Fibrillation N/A
Completed NCT02103101 - Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events N/A
Completed NCT05065502 - MIDAS Cluster Randomized Controlled Trial of Implementation Strategies to Optimize Use of Medications in VA Clinical Settings N/A
Recruiting NCT03965208 - Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation Phase 4
Completed NCT03318393 - Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO Phase 4
Recruiting NCT03288441 - Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia